Stay updated on mRNA-4157 Vaccine and Pembrolizumab in Melanoma Clinical Trial.
Sign up to get notified when there's something new on the mRNA-4157 Vaccine and Pembrolizumab in Melanoma Clinical Trial. page.

Latest updates to the mRNA-4157 Vaccine and Pembrolizumab in Melanoma Clinical Trial. page
- Check5 days agoChange DetectedThe web page has been updated to version 2.16.8, and it now includes a section on HHS Vulnerability Disclosure.SummaryDifference0.2%
- Check12 days agoChange DetectedThe web page has been updated from version 2.16.5 to version 2.16.6.SummaryDifference0.1%
- Check19 days agoChange DetectedA service alert has been added regarding planned maintenance starting July 25th, during which most services will be unavailable for over 24 hours.SummaryDifference1%
- Check26 days agoChange DetectedThe page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed. Additionally, a significant piece of information regarding the modernization of ClinicalTrials.gov data ingest in July 2025 has been deleted.SummaryDifference1%
- Check33 days agoNo Change Detected
- Check41 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference1%
- Check48 days agoChange DetectedThe page has updated the duration for a treatment protocol from 'up to 5 years' to 'up to 7 years' and has revised the dates related to the study timeline.SummaryDifference3%
Stay in the know with updates to mRNA-4157 Vaccine and Pembrolizumab in Melanoma Clinical Trial.
Enter your email address, and we'll notify you when there's something new on the mRNA-4157 Vaccine and Pembrolizumab in Melanoma Clinical Trial. page.